Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2015-03-11

Clinical Trial Update: Phase II Study of Vandetanib in Individuals With Kidney Cancer [Phase 2]

View source ↗

Summary

Phase II study of vandetanib in renal cancer and Von Hippel-Lindau syndrome has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Vandetanib (vandetanib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Renal Cancer, Von Hippel Lindau | Phase 2 | Status: COMPLETED | Results posted: 2015-03-11